Shopping Cart 0
Cart Subtotal
USD 0

Teva Pharmaceutical Industries Ltd (TEVA) - Medical Equipment - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Teva Pharmaceutical Industries Ltd (Teva) is a pharmaceutical company that carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines to treat disorders of the central nervous system (CNS), respiratory, cancer, women's health and other therapy areas. The company offers generic medicines in a range of dosage forms including capsules, tablets, injectables, liquids, inhalants, creams and ointments. Teva also provides over-the-counter (OTC) products, besides active pharmaceutical ingredients (APIs). It carries out OTC business principally through PGT Healthcare, a consumer healthcare joint venture with The Procter & Gamble Company (P&G). The company conducts its worldwide operations through a network of global subsidiaries. Teva is headquartered in Petach Tikva, Israel.

Teva Pharmaceutical Industries Ltd (TEVA)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 7

Teva Pharmaceutical Industries Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 8

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 9

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 10

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 11

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deal Details 14

Venture Financing 14

Gamida Cell Raises USD 10 Million In Series E Financing 14

Teva Pharma Industries Invests In MultiGene Vascular Systems 16

Partnerships 17

Teva Pharma Enters into Licensing Agreement with ProBioGen 17

Teva Pharma Enters into Licensing Agreement with Paxman Coolers 18

Teva Pharma Enters into Licensing Agreement with Brain Resource 19

Celmatix Enters into Partnership with Oncotest-Teva 20

Teva Pharma Enters into Agreement with Syqe Medical 21

Teva Pharma Enters into Agreement with Intel 22

MDxHealth Enters into Distribution Agreement with Teva Pharmaceutical 23

Oncotest-Teva Enters into Distribution Agreement with Guardant Health 24

Teva Pharma Enters into an Agreement with Microchips Biotech 25

MDxHealth Enters Into Agreement With Teva Pharma To Commercialize Two Cancer Tests In Israel 26

Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 27

Equity Offering 28

Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 28

Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares 30

Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares 32

American Well Raises USD10 Million in Private Placement of Shares 34

Debt Offering 35

Teva Pharma Prices Private Placement of 3.25% Notes Due 2022 for USD866.3 Million 35

Teva Pharma Prices Private Placement of 4.5% Notes Due 2025 for USD1,113.8 Million 36

Teva Pharma Prices Private Placement of 6.75% Notes Due 2028 for USD1.25 Billion 37

Teva Pharma Prices Private Placement of 6% Notes Due 2024 for USD1.25 Billion 38

Teva Pharma Plans to Raise USD5,000 Million in Public Offering of Debt Securities 39

Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 40

Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 42

Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 44

Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024 46

Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020 48

Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028 50

Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 52

Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 54

Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 56

Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 58

Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 60

Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 62

Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds 64

Asset Transactions 65

CooperSurgical Acquires PARAGARD from Teva Pharma for USD1.1 Billion 65

Acquisition 67

Allergan to Sell 10% Stake in Teva Pharma 67

Teva Pharma Sells Stake in Mesoblast 68

Teva Pharma Acquires Gecko Health Innovations 69

Teva Pharma Completes Acquisition Of NuPathe 70

Omron Healthcare To Acquire Minority Stake In Atonomics, Care Diagnostics Company 72

Teva Pharma Completes Acquisition of MicroDose Therapeutx 74

Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 75

Teva Pharmaceutical Industries Ltd-Key Competitors 77

Teva Pharmaceutical Industries Ltd-Key Employees 78

Teva Pharmaceutical Industries Ltd-Locations And Subsidiaries 80

Head Office 80

Other Locations & Subsidiaries 80

Joint Venture 89

Recent Developments 90

Financial Announcements 90

Aug 02, 2018: Teva reports second quarter 2018 financial results 90

May 03, 2018: Teva Reports First Quarter 2018 Financial Results 95

Feb 08, 2018: Teva Reports 2017 Full Year and Fourth Quarter Financial Results 100

Nov 02, 2017: Teva Reports Third Quarter 2017 Financial Results 108

Aug 03, 2017: Teva Reports Second Quarter 2017 Financial Results 112

May 11, 2017: Teva Reports First Quarter 2017 Financial Results 114

Feb 13, 2017: Teva Reports Full Year and Fourth Quarter 2016 Financial Results 118

Jan 06, 2017: Teva Provides 2017 Financial Outlook 126

Corporate Communications 128

Oct 30, 2017: Kare Schultz to Join Teva as President and Chief Executive Officer 128

Sep 19, 2017: Teva Completes Amendment to Credit Facilities 129

Sep 11, 2017: Teva Names Kare Schultz as President and Chief Executive Officer 130

Jul 23, 2017: Teva to Terminate Around 300 jobs in Israel 132

Jul 13, 2017: Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders 133

Apr 26, 2017: Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer 134

Feb 06, 2017: Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman 135

Product News 137

Feb 05, 2018: Amiko receives CE mark for three novel inhaler sensors 137

Other Significant Developments 138

Jul 17, 2018: Teva Highlights Key Milestones Achieved in the 2017 Social Impact Report 138

Dec 14, 2017: Teva Announces Restructuring Plan and Additional Measures to Improve Its Business and Financial Performance 139

Nov 27, 2017: Teva Announces New Organization Structure and Leadership Changes 141

Nov 21, 2017: Accelerating the Evolution of Pharma's Digital Landscape-Practices from Viseven 144

Appendix 145

Methodology 145

About GlobalData 145

Contact Us 145

Disclaimer 145


List Of Figure

List of Figures

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 7

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 8

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 9

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 10


List Of Table

List of Tables

Teva Pharmaceutical Industries Ltd, Medical Equipment, Key Facts, 2017 2

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 7

Teva Pharmaceutical Industries Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 8

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 9

Teva Pharmaceutical Industries Ltd, Deals By Market, 2012 to YTD 2018 10

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 11

Gamida Cell Raises USD 10 Million In Series E Financing 14

Teva Pharma Industries Invests In MultiGene Vascular Systems 16

Teva Pharma Enters into Licensing Agreement with ProBioGen 17

Teva Pharma Enters into Licensing Agreement with Paxman Coolers 18

Teva Pharma Enters into Licensing Agreement with Brain Resource 19

Celmatix Enters into Partnership with Oncotest-Teva 20

Teva Pharma Enters into Agreement with Syqe Medical 21

Teva Pharma Enters into Agreement with Intel 22

MDxHealth Enters into Distribution Agreement with Teva Pharmaceutical 23

Oncotest-Teva Enters into Distribution Agreement with Guardant Health 24

Teva Pharma Enters into an Agreement with Microchips Biotech 25

MDxHealth Enters Into Agreement With Teva Pharma To Commercialize Two Cancer Tests In Israel 26

Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 27

Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 28

Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares 30

Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares 32

American Well Raises USD10 Million in Private Placement of Shares 34

Teva Pharma Prices Private Placement of 3.25% Notes Due 2022 for USD866.3 Million 35

Teva Pharma Prices Private Placement of 4.5% Notes Due 2025 for USD1,113.8 Million 36

Teva Pharma Prices Private Placement of 6.75% Notes Due 2028 for USD1.25 Billion 37

Teva Pharma Prices Private Placement of 6% Notes Due 2024 for USD1.25 Billion 38

Teva Pharma Plans to Raise USD5,000 Million in Public Offering of Debt Securities 39

Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 40

Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 42

Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 44

Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024 46

Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020 48

Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028 50

Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 52

Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 54

Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 56

Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 58

Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 60

Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 62

Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds 64

CooperSurgical Acquires PARAGARD from Teva Pharma for USD1.1 Billion 65

Allergan to Sell 10% Stake in Teva Pharma 67

Teva Pharma Sells Stake in Mesoblast 68

Teva Pharma Acquires Gecko Health Innovations 69

Teva Pharma Completes Acquisition Of NuPathe 70

Omron Healthcare To Acquire Minority Stake In Atonomics, Care Diagnostics Company 72

Teva Pharma Completes Acquisition of MicroDose Therapeutx 74

Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 75

Teva Pharmaceutical Industries Ltd, Key Competitors 77

Teva Pharmaceutical Industries Ltd, Key Employees 78

Teva Pharmaceutical Industries Ltd, Subsidiaries 80

Teva Pharmaceutical Industries Ltd, Joint Venture 89

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Teva Pharmaceutical Industries Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Teva Pharmaceutical Industries Ltd (Teva) is a pharmaceutical company that carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines to treat disorders of the central nervous system (CNS), respiratory, cancer, women's health and other therapy areas. The company offers generic medicines in a range of dosage forms including capsules, tablets, injectables, liquids, inhalants, creams and ointments. Teva also provides over-the-counter (OTC) products, besides active pharmaceutical ingredients (APIs). It carries out OTC business principally through PGT Healthcare, a consumer healthcare joint venture with The Procter & Gamble Company (P&G). The company conducts its worldwide operations through a network of global subsidiaries. Teva is headquartered in Petach Tikva, Israel.

Teva Pharmaceutical Industries Ltd (TEVA)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 7

Teva Pharmaceutical Industries Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 8

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 9

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 10

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 11

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deal Details 14

Venture Financing 14

Gamida Cell Raises USD 10 Million In Series E Financing 14

Teva Pharma Industries Invests In MultiGene Vascular Systems 16

Partnerships 17

Teva Pharma Enters into Licensing Agreement with ProBioGen 17

Teva Pharma Enters into Licensing Agreement with Paxman Coolers 18

Teva Pharma Enters into Licensing Agreement with Brain Resource 19

Celmatix Enters into Partnership with Oncotest-Teva 20

Teva Pharma Enters into Agreement with Syqe Medical 21

Teva Pharma Enters into Agreement with Intel 22

MDxHealth Enters into Distribution Agreement with Teva Pharmaceutical 23

Oncotest-Teva Enters into Distribution Agreement with Guardant Health 24

Teva Pharma Enters into an Agreement with Microchips Biotech 25

MDxHealth Enters Into Agreement With Teva Pharma To Commercialize Two Cancer Tests In Israel 26

Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 27

Equity Offering 28

Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 28

Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares 30

Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares 32

American Well Raises USD10 Million in Private Placement of Shares 34

Debt Offering 35

Teva Pharma Prices Private Placement of 3.25% Notes Due 2022 for USD866.3 Million 35

Teva Pharma Prices Private Placement of 4.5% Notes Due 2025 for USD1,113.8 Million 36

Teva Pharma Prices Private Placement of 6.75% Notes Due 2028 for USD1.25 Billion 37

Teva Pharma Prices Private Placement of 6% Notes Due 2024 for USD1.25 Billion 38

Teva Pharma Plans to Raise USD5,000 Million in Public Offering of Debt Securities 39

Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 40

Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 42

Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 44

Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024 46

Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020 48

Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028 50

Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 52

Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 54

Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 56

Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 58

Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 60

Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 62

Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds 64

Asset Transactions 65

CooperSurgical Acquires PARAGARD from Teva Pharma for USD1.1 Billion 65

Acquisition 67

Allergan to Sell 10% Stake in Teva Pharma 67

Teva Pharma Sells Stake in Mesoblast 68

Teva Pharma Acquires Gecko Health Innovations 69

Teva Pharma Completes Acquisition Of NuPathe 70

Omron Healthcare To Acquire Minority Stake In Atonomics, Care Diagnostics Company 72

Teva Pharma Completes Acquisition of MicroDose Therapeutx 74

Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 75

Teva Pharmaceutical Industries Ltd-Key Competitors 77

Teva Pharmaceutical Industries Ltd-Key Employees 78

Teva Pharmaceutical Industries Ltd-Locations And Subsidiaries 80

Head Office 80

Other Locations & Subsidiaries 80

Joint Venture 89

Recent Developments 90

Financial Announcements 90

Aug 02, 2018: Teva reports second quarter 2018 financial results 90

May 03, 2018: Teva Reports First Quarter 2018 Financial Results 95

Feb 08, 2018: Teva Reports 2017 Full Year and Fourth Quarter Financial Results 100

Nov 02, 2017: Teva Reports Third Quarter 2017 Financial Results 108

Aug 03, 2017: Teva Reports Second Quarter 2017 Financial Results 112

May 11, 2017: Teva Reports First Quarter 2017 Financial Results 114

Feb 13, 2017: Teva Reports Full Year and Fourth Quarter 2016 Financial Results 118

Jan 06, 2017: Teva Provides 2017 Financial Outlook 126

Corporate Communications 128

Oct 30, 2017: Kare Schultz to Join Teva as President and Chief Executive Officer 128

Sep 19, 2017: Teva Completes Amendment to Credit Facilities 129

Sep 11, 2017: Teva Names Kare Schultz as President and Chief Executive Officer 130

Jul 23, 2017: Teva to Terminate Around 300 jobs in Israel 132

Jul 13, 2017: Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders 133

Apr 26, 2017: Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer 134

Feb 06, 2017: Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman 135

Product News 137

Feb 05, 2018: Amiko receives CE mark for three novel inhaler sensors 137

Other Significant Developments 138

Jul 17, 2018: Teva Highlights Key Milestones Achieved in the 2017 Social Impact Report 138

Dec 14, 2017: Teva Announces Restructuring Plan and Additional Measures to Improve Its Business and Financial Performance 139

Nov 27, 2017: Teva Announces New Organization Structure and Leadership Changes 141

Nov 21, 2017: Accelerating the Evolution of Pharma's Digital Landscape-Practices from Viseven 144

Appendix 145

Methodology 145

About GlobalData 145

Contact Us 145

Disclaimer 145


List Of Figure

List of Figures

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 7

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 8

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 9

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 10


List Of Table

List of Tables

Teva Pharmaceutical Industries Ltd, Medical Equipment, Key Facts, 2017 2

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 7

Teva Pharmaceutical Industries Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 8

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 9

Teva Pharmaceutical Industries Ltd, Deals By Market, 2012 to YTD 2018 10

Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 11

Gamida Cell Raises USD 10 Million In Series E Financing 14

Teva Pharma Industries Invests In MultiGene Vascular Systems 16

Teva Pharma Enters into Licensing Agreement with ProBioGen 17

Teva Pharma Enters into Licensing Agreement with Paxman Coolers 18

Teva Pharma Enters into Licensing Agreement with Brain Resource 19

Celmatix Enters into Partnership with Oncotest-Teva 20

Teva Pharma Enters into Agreement with Syqe Medical 21

Teva Pharma Enters into Agreement with Intel 22

MDxHealth Enters into Distribution Agreement with Teva Pharmaceutical 23

Oncotest-Teva Enters into Distribution Agreement with Guardant Health 24

Teva Pharma Enters into an Agreement with Microchips Biotech 25

MDxHealth Enters Into Agreement With Teva Pharma To Commercialize Two Cancer Tests In Israel 26

Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 27

Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 28

Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares 30

Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares 32

American Well Raises USD10 Million in Private Placement of Shares 34

Teva Pharma Prices Private Placement of 3.25% Notes Due 2022 for USD866.3 Million 35

Teva Pharma Prices Private Placement of 4.5% Notes Due 2025 for USD1,113.8 Million 36

Teva Pharma Prices Private Placement of 6.75% Notes Due 2028 for USD1.25 Billion 37

Teva Pharma Prices Private Placement of 6% Notes Due 2024 for USD1.25 Billion 38

Teva Pharma Plans to Raise USD5,000 Million in Public Offering of Debt Securities 39

Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 40

Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 42

Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 44

Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024 46

Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020 48

Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028 50

Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 52

Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 54

Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 56

Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 58

Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 60

Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 62

Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds 64

CooperSurgical Acquires PARAGARD from Teva Pharma for USD1.1 Billion 65

Allergan to Sell 10% Stake in Teva Pharma 67

Teva Pharma Sells Stake in Mesoblast 68

Teva Pharma Acquires Gecko Health Innovations 69

Teva Pharma Completes Acquisition Of NuPathe 70

Omron Healthcare To Acquire Minority Stake In Atonomics, Care Diagnostics Company 72

Teva Pharma Completes Acquisition of MicroDose Therapeutx 74

Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 75

Teva Pharmaceutical Industries Ltd, Key Competitors 77

Teva Pharmaceutical Industries Ltd, Key Employees 78

Teva Pharmaceutical Industries Ltd, Subsidiaries 80

Teva Pharmaceutical Industries Ltd, Joint Venture 89

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Teva Pharmaceutical Industries Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.